However, the optimised copper(II) complexes could be radiolabelled with copper-64 (PET imaging radioisotope) or copper-67 (therapeutic/SPECT imaging radioisotope), offering a route to the development of CXCR4-targeted theranostics for cancer imaging and therapy. This evidence concerns the gene CXCR4 and cancer.